Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Clinical Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
Departments

Decisions About Intensity of Glycemic Control Should Depend on Age and Functional Status

  1. Michael Pignone, MD, MPH
    Clinical Diabetes 2009 Oct; 27(4): 147-148. https://doi.org/10.2337/diaclin.27.4.147
    PreviousNext
    • Article
    • Info & Metrics
    • PDF
    Loading

    STUDY

    Huang ES, Zhang Q, Gandra N, Chin MH, Meltzer DO: The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med 149:11-19, 2008

    SUMMARY

    Design. A decision analysis.

    Subjects. Adults ages 60-80 years with diabetes.

    Methods. The authors developed a simulation model to understand the magnitude of the potential benefits of intensive (target A1C < 7.0%) versus moderate (target A1C < 7.9%) glycemic control in older adults with diabetes (both new-onset and of different levels of duration) and a range of comorbid illnesses and functional limitations. The model parameters were drawn from available trials and cohort studies. Comorbidity and functional limitations were categorized using a previously validated framework and were used to model life expectancy. The potential benefits of intensive control were expressed in average quality-adjusted life-days gained. Diabetes-related complications (e.g., blindness, end-stage renal disease, amputation, and myocardial infarction) were assigned health values (utilities) based on previous studies. The model did not consider costs and did not account for decrements in quality of life or complications (e.g., hypoglycemia) from intensive treatment. Use of other cardiovascular risk-reducing therapies was considered, with the levels based on older survey data.

    Results. The potential benefits of intensive glycemic control were relatively small (51-116 quality-adjusted life-days gained) and appeared to depend on age and the presence of functional disability. When life expectancy was < 5 years, intensive control produced little benefit, even under optimistic assumptions.

    Conclusions. Decisions about intensive glycemic control in older adults should consider life expectancy, which can be assessed based on age and functional status. Older adults with limited life expectancy are unlikely to benefit from intensive control compared with moderate control.

    COMMENTARY

    The care of older adults with diabetes is challenging. The incidence of diabetes-related complications increases with age and duration of diabetes. However, the treatment-related adverse effects and competing causes of morbidity and mortality also become more common. Few trials have focused specifically on understanding the benefits and downsides of therapies in older adults. As a result, decisions about whether to implement interventions such as intensive glycemic control are often based on extrapolation from data collected mainly in middle-aged trial participants.

    Achieving intensive glycemic control can be difficult and can require considerable resources and effort on the part of patients, providers, and health care systems. Therefore, the decision to pursue intensive control should depend on the magnitude of the potential net benefit.

    Given the limited trial data, Huang et al. developed a simulation model to better understand the potential benefits of intensive glycemic control in older adults. They used available data from cohort studies and from the U.K. Prospective Diabetes Study1 to examine the magnitude of benefits from intensive control for patients of different ages, durations of diabetes, and levels of functional ability. Not surprisingly, they found that the potential benefits of intensive control depended on life expectancy (derived from age and functional status)2 and duration of diabetes. Those with limited life expectancy (< 5 years) would receive little benefit from intensive, compared to moderate, control. The potential benefits were larger for younger patients but did not differ greatly based on duration of diabetes.

    The decision to express the model results in quality-adjusted life-days makes it difficult to know whether the potential benefits of intensive control make sense in patients with intermediate (5- to 10-year) life expectancies. Consideration of the costs of intensive (compared to moderate) glycemic control and calculation of a cost per quality-adjusted life-year gained would have helped clarify the yield of intensive therapy and allowed comparison against other potential resource uses.

    Several features of the model suggest that the estimates of potential benefit are optimistic and that the actual benefits may be smaller than described. First, the model assumes that intensive glycemic control reduces cardiovascular complications, which is controversial in light of the recent findings from the Action to Control Cardiovascular Risk in Diabetes study.3 Assuming no cardiovascular reduction from better control reduced the potential benefits by > 50% across age-groups. Second, the model does not appear to account for treatment-related adverse effects (hypoglycemia) or the decrement in quality of life and increased patient time required to achieve intensive control. Third, the levels of use of other effective therapies were assumed to be low (e.g., 26% for ACE inhibitors) or were modeled indirectly (modeling of lipid levels from national survey data collected when statin use was less common). Assuming greater use of concurrent therapies would reduce the potential absolute benefits of intensive control.

    Despite these limitations, the modeling work by Huang et al. represents an important advance in how we consider whether to aim for intensive glycemic control in older adults with type 2 diabetes. Further modeling, coupled with focused primary data collection and real-world testing of physicians' ability to use an age- and functional status—based life expectancy assessment, will help us better target intensive control to those most likely to benefit from it.

    Footnotes

    • Michael Pignone, MD, MPH, is an associate professor of medicine at the University of North Carolina Department of Medicine in Chapel Hill and an associate editor of Clinical Diabetes.

    • American Diabetes Association(R) Inc., 2009

    REFERENCES

    1. ↵
      1. U.K. Prospective Diabetes Study Group
      : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      1. Saliba D,
      2. Elliott M,
      3. Rubenstein LZ,
      4. Solomon DH,
      5. Young RT,
      6. Kamberg CJ,
      7. Roth C,
      8. MacLean CH,
      9. Shekelle PG,
      10. Sloss EM,
      11. Wenger NS
      : The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49:1691-1699, 2001
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      1. Gerstein HC,
      2. Miller ME,
      3. Byington RP,
      4. Goff DC, Jr,
      5. Bigger JT,
      6. Buse JB,
      7. Cushman WC,
      8. Genuth S,
      9. Ismail-Beigi F,
      10. Grimm RH, Jr,
      11. Probstfield JL,
      12. Simons-Morton DG,
      13. Friedewald WT,
      14. the Action to Control Cardiovascular Risk in Diabetes Study Group
      : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559, 2008
      OpenUrlCrossRefPubMed
    View Abstract
    PreviousNext
    Back to top

    In this Issue

    October 2009, 27(4)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Clinical Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Decisions About Intensity of Glycemic Control Should Depend on Age and Functional Status
    (Your Name) has forwarded a page to you from Clinical Diabetes
    (Your Name) thought you would like to see this page from the Clinical Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Decisions About Intensity of Glycemic Control Should Depend on Age and Functional Status
    Michael Pignone
    Clinical Diabetes Oct 2009, 27 (4) 147-148; DOI: 10.2337/diaclin.27.4.147

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Decisions About Intensity of Glycemic Control Should Depend on Age and Functional Status
    Michael Pignone
    Clinical Diabetes Oct 2009, 27 (4) 147-148; DOI: 10.2337/diaclin.27.4.147
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • STUDY
      • SUMMARY
      • COMMENTARY
      • Footnotes
      • REFERENCES
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    Departments

    • Case Reports on Diabetes-Related Outcomes for Pregnant Women in the National Diabetes Prevention Program
    • Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients
    • Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia
    Show more Departments

    Landmark Studies

    • Television Viewing Increases Risk of Type 2 Diabetes, Cardiovascular Disease, and Mortality
    • The Effect of Fruit and Vegetable Intake on the Incidence of Diabetes
    • High-Protein and Low-Glycemic Diets Improve Weight Maintenance Among Overweight Adults
    Show more Landmark Studies

    Similar Articles

    Navigate

    • Current Issue
    • Papers in Press
    • Abridged Standards of Care
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Clinical Diabetes Print ISSN: 0891-8929, Online ISSN: 1945-4953.